Lamellar sliver: devastating complication of recutting after LASIK

Article

A lamellar sliver is a devastating complication resulting from recutting flaps during LASIK enhancement procedures.

A lamellar sliver is a devastating complication resulting from recutting flaps during LASIK enhancement procedures, said Jonathan Song, MD, from the Doheny Eye Institute, Los Angeles, US.

Retreatment, he noted, is needed in 3–10% of patients who undergo LASIK. After LASIK was initially introduced, recutting was advised after six months; later, relifting was advised after one year and then after two years. However, a serious complication, lamellar sliver, which is tissue missing from the flap as a result of recutting, was reported to have caused irregular astigmatism and decreased visual acuity. Twelve patients were found to have this complication after procedures performed by nine experienced surgeons; all patients had irregular astigmatism, significant loss of best-corrected visual acuity, and very high subjective visual difficulties.

To prevent the lamellar sliver, Dr Song advised surgeons to relift all flaps if possible - relifting can be done up to 10 years using a needle or a depression technique.

“The technique that I prefer in patients with a relatively new flap is where the edge of the flap can be depressed and a blunt instrument used to go inside the edge,” he said. “A spatula can be used to loosen any adhesion.”

After retreatment, the edges should be clean and any loose epithelium removed. A bandage contact lens can be considered. If the flap is difficult to lift, he suggested converting to surface ablation with mitomycin C.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.